Loading news...
Bethany J. Cavanagh sold 6,198 direct shares for a transaction value of approximately $216,933 at a weighted average price of around $35.00 per share. The sale represented 15.11% of direct post-transaction holdings, reducing direct ownership from 41,011 to 34,813 shares.
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Christine Bellon sold 1,371 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $34.00, for a total transaction of $46,614.00. Following the sale, the insider directly owned 95,667 shares of the company's stock, valued at
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Christine Bellon sold 18,629 shares of Beam Therapeutics stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $34.61, for a total value of $644,749.69. Following the transaction, the insider directly owned 97,038 shares in the company, valued at
SG Americas Securities LLC grew its position in Beam Therapeutics Inc. (NASDAQ: BEAM) by 498.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 43,220 shares of the company's stock after buying an additional 36,004 shares during the period. SG Americas Securities LLC's holdings
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a potential FDA accelerated approval pathway, derisking the lead pipeline and providing a major 2026 catalyst. Risto-cel targets Sickle Cell Disease but faces a crowded ex vivo market; best-in-class data and BLA submission are expected by end of 2026.
Beam Therapeutics jumps 22% after outlining 2026 pipeline goals, including accelerated approval plans for BEAM-302 and a potential risto-cel BLA filing.
Beam stock launched Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, BEAM-302.
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026 Expansion of Liver-targeted Genetic Disease Franchise Underway with New Program to be Announced in First Half of 2026 Ended 2025 with Estimated $1.25 Billion in Cash, Cash Equivalents and Marketable Securities; Projected Operating Runway Extension into 2029 Supports Anticipated risto-cel Launch and Execution of BEAM-302 Pivotal Development Plan CAMBRIDGE, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) today announced continued progress toward its mission to build a sustainable, predictable model for the advancement of precision genetic medicines, highlighting recent updates for its liver-targeted genetic disease and hematology franchises and strategic priorities in 2026, supported by an extended anticipated operating runway.
Cathie Wood's ARK Invest is entering 2026 with a noticeably sharper bet on early-stage biotechnology, while selectively reducing exposure to consumer technology
Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.
Cathie Wood's ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while
Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (TSLA) and Rocket Lab (RKLB).Sellin
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P.
Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Capital Fund Management S.A. acquired a new stake in shares of Beam Therapeutics Inc. (NASDAQ: BEAM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 38,438 shares of the company's stock, valued at approximately $654,000. Several other institutional investors have also made
Beam Therapeutics Inc. remains a Strong Buy, supported by robust BEAM-101 phase 1/2 BEACON trial data in sickle cell disease. BEAM-101 consistently achieved >60% Hemoglobin F induction,
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the 2025 Jefferies London Healthcare Conference on Wednesday, November 19, 2025, at 3:30 p.m.